
TYME
Healthcare · Biotechnology · $53.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 9, 2022 | Before the open | — | -0.04 | — |
| May 25, 2022 | Before the open | — | -0.04 | — |
| Feb 11, 2022 | Before the open | -0.06 | -0.05 | +16.7% |
| Nov 8, 2021 | Before the open | -0.06 | -0.05 | +16.7% |
| Aug 10, 2021 | Before the open | -0.06 | -0.05 | +16.7% |
| Jun 10, 2021 | After the close | — | -0.04 | — |
| Feb 3, 2021 | After the close | -0.06 | -0.05 | +16.7% |
| Nov 12, 2020 | Before the open | -0.06 | -0.05 | +16.7% |
| Aug 12, 2020 | After the close | -0.06 | -0.07 | -16.7% |
| May 20, 2020 | After the close | -0.07 | -0.04 | +42.9% |
| Feb 5, 2020 | Before the open | -0.06 | -0.06 | 0.0% |
| Nov 4, 2019 | After the close | -0.06 | -0.05 | +16.7% |
| Aug 8, 2019 | Before the open | -0.07 | -0.03 | +57.1% |
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which…
| Jun 12, 2019 | Before the open | -0.08 | -0.10 | -25.0% |
| Feb 11, 2019 | Before the open | -0.08 | -0.08 | 0.0% |
| Nov 5, 2018 | Before the open | -0.07 | -0.07 | 0.0% |
| Jul 31, 2018 | After the close | -0.08 | -0.07 | +12.5% |
| Jun 13, 2018 | After the close | -0.07 | -0.06 | +14.3% |
| Feb 7, 2018 | Before the open | -0.08 | -0.06 | +28.0% |